Antimicrobial Stewardship Activities in Public Healthcare Facilities in South Africa: A Baseline for Future Direction.
South Africa
antimicrobial resistance
antimicrobial stewardship programmes
primary healthcare
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
received:
29
06
2021
revised:
02
08
2021
accepted:
03
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is a growing problem worldwide, including South Africa, where an AMR National Strategy Framework was implemented to instigate antimicrobial stewardship programmes (ASPs) and improve antimicrobial prescribing across sectors. To address the need to assess progress, a sequential mixed methodology with an explanatory research design was employed. In Phase 1, a self-administered questionnaire was completed by healthcare professionals (HCPs) from 26 public sector healthcare facilities across South Africa to assess compliance with the Framework. The results were explored in Phase 2 through 10 focus group discussions and two in-depth interviews, including 83 participants. Emerging themes indicated that public healthcare facilities across South Africa are facing many challenges, especially at entry level primary healthcare (PHC) facilities, where antimicrobial stewardship activities and ASPs are not yet fully implemented. Improved diagnostics and surveillance data are a major shortcoming at these facilities. Continuous education for HCPs is deficient, especially for the majority of prescribers at PHC level and health campaigns are nearly non-existent. Involvement and visibility of management at certain facilities is a serious shortfall. Consequently, it is important to call attention to the challenges faced with improving antimicrobial prescribing across countries and address these to reduce AMR, especially in PHC facilities, being the first point of access to healthcare for the vast majority of patients in developing countries.
Identifiants
pubmed: 34439046
pii: antibiotics10080996
doi: 10.3390/antibiotics10080996
pmc: PMC8388942
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MC_PC_16090
Pays : United Kingdom
Organisme : Sefako Makgatho Health Sciences University
ID : Research Support - Cost Centre D203
Références
Virulence. 2013 Feb 15;4(2):192-202
pubmed: 23361336
JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab080
pubmed: 34223139
S Afr Med J. 2017 Jan 30;107(2):119-122
pubmed: 28220736
S Afr Med J. 2017 Jan 30;107(2):115-118
pubmed: 28220735
Global Health. 2020 Nov 11;16(1):109
pubmed: 33176810
Kolner Z Soz Sozpsychol. 2017;69(Suppl 2):107-131
pubmed: 28989188
Hosp Pract (1995). 2019 Oct;47(4):203-210
pubmed: 31359809
Clin Microbiol Infect. 2017 Nov;23(11):812-818
pubmed: 28712667
Life (Basel). 2021 Jun 07;11(6):
pubmed: 34200116
S Afr Med J. 2016 Apr 07;106(5):59
pubmed: 27138669
Front Pharmacol. 2018 May 29;9:442
pubmed: 29896100
Int J Antimicrob Agents. 2020 Dec;56(6):106189
pubmed: 33045348
Expert Rev Anti Infect Ther. 2017 Oct;15(10):963-972
pubmed: 28922959
Antibiotics (Basel). 2020 Feb 02;9(2):
pubmed: 32024295
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
J Comp Eff Res. 2021 Aug;10(12):1019-1052
pubmed: 34241546
PLoS One. 2017 Dec 21;12(12):e0189621
pubmed: 29267306
Hosp Pract (1995). 2019 Feb;47(1):53-58
pubmed: 29757036
Curr Med Res Opin. 2020 Feb;36(2):301-327
pubmed: 31794332
Expert Rev Anti Infect Ther. 2018 Jan;16(1):77-84
pubmed: 29251001
Front Pharmacol. 2016 Feb 12;7:21
pubmed: 26903867
Int J Gen Med. 2021 Feb 18;14:515-530
pubmed: 33633461
Expert Rev Anti Infect Ther. 2017 Jul;15(7):713-721
pubmed: 28425828
Hosp Pract (1995). 2020 Mar 14;48(2):51-67
pubmed: 32196395
Antimicrob Resist Infect Control. 2018 Nov 15;7:136
pubmed: 30473786
BMJ. 2020 May 18;369:m1983
pubmed: 32423901
BMC Public Health. 2016 Aug 22;16:724
pubmed: 27545670
Expert Rev Anti Infect Ther. 2015;13(12):1547-56
pubmed: 26358203
Int J Qual Health Care. 2019 Jun 1;31(5):338-345
pubmed: 30169688
Antimicrob Resist Infect Control. 2019 Feb 12;8:35
pubmed: 30805182
Expert Rev Anti Infect Ther. 2021 Jul 26;:1-23
pubmed: 34038294
J Sport Health Sci. 2019 Nov;8(6):516-519
pubmed: 31720060
Expert Opin Pharmacother. 2019 Dec;20(18):2237-2255
pubmed: 31762343
Expert Rev Anti Infect Ther. 2021 May 2;:1-13
pubmed: 33724147
J Family Med Prim Care. 2019 Jun;8(6):1867-1871
pubmed: 31334147
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:73-8
pubmed: 23640191
BMC Infect Dis. 2017 Sep 11;17(1):616
pubmed: 28893183
Antimicrob Resist Infect Control. 2019 Aug 13;8:137
pubmed: 31417673
Health Econ. 2017 Jul;26(7):844-852
pubmed: 27683202
Expert Rev Anti Infect Ther. 2015 Feb;13(2):279-89
pubmed: 25495147
PLoS One. 2016 Jul 25;11(7):e0159467
pubmed: 27454581
Nurse Educ Today. 2016 Jan;36:58-63
pubmed: 26254674
PLoS Med. 2019 Mar 29;16(3):e1002774
pubmed: 30925166
Expert Rev Anti Infect Ther. 2021 Apr;19(4):537-546
pubmed: 32990480
BMJ Open. 2017 May 2;7(4):e014345
pubmed: 28465306
JBI Database System Rev Implement Rep. 2016 Jun;14(6):42-51
pubmed: 27532648
J Infect Dis. 2020 Mar 16;221(Suppl 2):S148-S155
pubmed: 32176788
Nurs Health Sci. 2013 Sep;15(3):398-405
pubmed: 23480423
Front Public Health. 2020 Aug 27;8:454
pubmed: 32974264
Microbiol Spectr. 2018 Mar;6(2):
pubmed: 29600770
J Public Health (Oxf). 2017 Mar 1;39(1):8-13
pubmed: 26944074
BMC Health Serv Res. 2017 Nov 21;17(1):747
pubmed: 29157244
J Chemother. 2020 Dec;32(8):456-459
pubmed: 32114964
Front Pharmacol. 2017 Nov 09;8:751
pubmed: 29163151
Int J Infect Dis. 2017 Nov;64:100-106
pubmed: 28893672
S Afr Med J. 2018 Mar 28;108(4):304-310
pubmed: 29629681
Int J Clin Pharm. 2020 Aug;42(4):1227-1236
pubmed: 32458227
JAC Antimicrob Resist. 2020 Oct 22;2(4):dlaa092
pubmed: 34223045
Pediatr Infect Dis J. 2019 Feb;38(2):122-126
pubmed: 29677085
J Glob Antimicrob Resist. 2019 Jun;17:132-136
pubmed: 30557686
Clin Microbiol Infect. 2019 Jan;25(1):20-25
pubmed: 29625170
Nat Rev Microbiol. 2019 Jan;17(1):3
pubmed: 30467331
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1273-1280
pubmed: 28776442
BMJ Glob Health. 2019 May 9;4(3):e001239
pubmed: 31179029
Br J Clin Pharmacol. 2018 Apr;84(4):708-715
pubmed: 29236303
JAC Antimicrob Resist. 2020 Feb 18;2(1):dlaa001
pubmed: 34222959
Health Policy Plan. 2020 Oct 1;35(8):973-982
pubmed: 32743655
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
PLoS One. 2015 Mar 20;10(3):e0117710
pubmed: 25793497
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Infect Dis Clin North Am. 2020 Mar;34(1):31-49
pubmed: 31836327
Public Health Action. 2013 Jun 21;3(2):118-24
pubmed: 26393013
J Glob Antimicrob Resist. 2020 Sep;22:317-324
pubmed: 32247077
Front Pharmacol. 2020 Mar 20;11:108
pubmed: 32265688
Infect Drug Resist. 2020 Dec 29;13:4713-4738
pubmed: 33402841
Hosp Pract (1995). 2021 Aug;49(3):184-193
pubmed: 33566710
Hosp Pract (1995). 2018 Apr;46(2):77-87
pubmed: 29426263
Expert Rev Clin Pharmacol. 2019 Feb;12(2):159-168
pubmed: 30407089
Infect Dis Clin North Am. 2020 Mar;34(1):51-65
pubmed: 31836331
BMJ Open. 2017 Jul 26;7(7):e016264
pubmed: 28751488
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):1-4
pubmed: 26954076
Ther Adv Drug Saf. 2014 Dec;5(6):229-41
pubmed: 25436105
J Chemother. 2021 Feb;33(1):21-31
pubmed: 32693710
J Chemother. 2019 Nov - Dec;31(7-8):378-387
pubmed: 31145043